Organic & Biomolecular Chemistry

PAPER

Cite this: Org. Biomol. Chem., 2013, 11, 1171

Received 20th October 2012, Accepted 10th December 2012

DOI: 10.1039/c2ob27050a

Development of a new cascade reaction for convergent synthesis of pyrazolo[1,5-a]quinoline derivatives under transition-metal-free conditions†

Jun-ya Kato, Hiroshi Aoyama and Tsutomu Yokomatsu*

A novel method for the synthesis of pyrazolo[1,5-a]quinolines under the transition-metal-free conditions has been developed. This method involves a novel combination of aromatic nucleophilic substitution and Knoevenagel condensation reactions to give pyrazolo[1,5-a]guinolines.

Introduction

www.rsc.org/obc

Recently, the pyrazolo [1,5-a] quinoline subunit has been applied to useful compounds that display a biological and material function. In particular, 3-substituted pyrazolo[1,5-a]quinoline derivatives have been developed for dopamine D4 antagonist agents,¹ GPR109a agonist agents,² and organic light-emitting device agents.³ These reports suggest to us that the pyrazolo [1,5-a] quinoline skeleton may be a potentially useful privileged scaffold in the discovery of biologically and materially active compounds.⁴ However, besides these examples, the pyrazolo[1,5-a]quinoline subunit has not been applied to seek further biologically and materially active compounds, which might be due to the lack of general methods for the synthesis of pyrazolo[1,5-*a*]quinoline derivatives.

Previous methods for the synthesis of pyrazolo[1,5-a]quinolones involve (1) a 1,3-dipolar cycloaddition reaction of N-iminoquinolines with acetylene esters;⁵ (2) a nucleophilic reaction of *N*-iminoquinolines with ketene dithioacetals; 6 (3) an alkenylation/cyclization reaction of N-iminoquinolines with alkenyl iodides;⁷ (4) a direct oxidative coupling reaction of phenylpyrazoles with internal alkynes;8 and other approaches.9 These methods require an inconvenient multi-step synthesis for the required substrates. Therefore, to develop medicinally and materially significant compounds possessing a pyrazolo[1,5-a]quinoline subunit, a general and more facile approach to the synthesis of pyrazolo[1,5-a]quinolines and related compounds has become more desirable.

shown in Scheme 1. In this cascade reaction, the intermolecular aromatic nucleophilic substitution (S_NAr) of 2-fluorobenzaldehyde (1a) with 3,5-dimethyl-1H-pyrazole (2a) having a carboethoxy group at the 4-position is first conducted in the presence of a base to give the expected 1-substituted 3,5dimethylpyrazole (3aa). In these intermediates, the 5-methyl group would be anionically more activated than the 3-methyl group under the conditions, since the trace anion generated at the 5-methyl group is favourably conjugated to the carboethoxy group.¹⁰ The trace anions of **3aa** are successfully expected to proceed through the intramolecular Knoevenagel condensation reaction to give the desired pyrazolo[1,5-a]quinoline 4aa. This S_NAr/Knoevenagel cyclization cascade reaction allows us to synthesize a variety of pyrazolo[1,5-a]quinolines without using any transition metal catalysts upon fine-tuning a combination of two substrates. In this paper, we describe the preliminary results of our studies.

Results and discussion

Optimization of the reaction conditions

First, we examined the S_NAr/Knoevenagel cyclization cascade reaction utilizing 1a and 2a as model substrates to optimize





View Article Online

Published on 11 December 2012. Downloaded by University of Pittsburgh on 30/10/2014 14:25:26.

Scheme 1 New cascade reaction for synthesis of pyrazolo[1,5-a]quinoline.

School of Pharmacy. Tokyo University of Pharmacy and Life Sciences. 1432-1 Horinouchi, Hachioji, Tokyo 192-0392, Japan. E-mail: yokomatu@toyaku.ac.jp; Fax: +81-42-676-3239; Tel: +81-42-676-3239

[†]Electronic supplementary information (ESI) available: Copies of ¹H and ¹³C NMR spectra for all new compounds; X-ray analysis data for compound 9ca. CCDC 900469. For ESI and crystallographic data in CIF or other electronic format see DOI: 10.1039/c2ob27050a

Table 1 Optimization of the S_NAr/Knoevenagel cyclization cascade reaction^a



^{*a*} All reactions were carried out in the presence of pyrazole (2a) (1.2 mmol), 2-fluorobenzaldehyde (1a) (1.0 mmol), and base (3.0 mmol) in the indicated solvent (5 mL) for 8 h. ^{*b*} Isolated yield.

suitable bases and solvents. The results are shown in Table 1. When **1a** was treated with **2a** in the presence of an excess of K_2CO_3 (3 equiv.) in DMF at 120 °C for 8 h, the desired pyrazolo-[1,5-*a*]quinoline **4aa** was obtained with 80% yield as expected (Table 1, entry 1). Although a very slow reaction was observed when the reaction was carried out with Na₂CO₃ in place of K_2CO_3 (Table 1, entry 2), it was found that Cs₂CO₃ and K_3PO_4 are also effective bases for this cascade reaction in DMF at 120 °C to give **4aa** in slightly lower yields (Table 1, entries 3 and 4). It is noteworthy that organic bases such as Et₃N and DBU were highly detrimental to this reaction and no desired products were detected for this reaction. No reaction occurred without a base in DMF at 120 °C.

Choice of the solvents is critical for this cascade reaction. When the reaction was carried out in the presence of K_2CO_3 at reflux upon switching the solvents from DMF to dioxane or toluene, no desired product was detected. However, DMSO was found to also be an efficient solvent to give **4aa** in a comparative yield (Table 1 entry 1 *vs.* 6). The cascade reaction was highly affected by the reaction temperature; the yield significantly decreased when the reaction was conducted below 120 °C (Table 1, entry 1 *vs.* 7, 8). Based on these results, at this stage, the optimal conditions for the cascade reaction were determined to be as conducted with 300 mol% of inexpensive K_2CO_3 in DMF at 120 °C for 8 h.

When the reaction was stopped within 1 h for the conditions of entry 1, **3aa** was isolated in a 7% yield along with 37% of **4aa** (Table 1, entry 9 and Scheme 1). The obtained **3aa** was resubmitted to the same conditions to entry 1 for 8 h to give **4aa** in a 31% isolated yield (Scheme 2). These experiments show that the proposed cascade reaction works well as expected (Scheme 1). We believe that the present cascade reaction is the first example in which the inactivated methyl group of the pyrazoles participates in the Knoevenagel cyclization **Organic & Biomolecular Chemistry**



Scheme 2 Knoevenagel condensation of 3aa

upon ary lating at the nitrogen of the pyrazoles through the $\rm S_NAr$ substitution. 11

Scope of 2-fluorobenzaldehydes

With the optimized conditions in hand, the scope and generality of the one-pot cascade reactions were investigated. First, **2a** was reacted with a variety of 2-fluorobenzaldehydes possessing a representative functional group on the aromatic ring. The results are shown in Table 2. Almost all of the tested combinations successfully produced the desired pyrazolo[1,5-*a*]quinolines **4ba–4na** with low to good isolated yields.

The results suggest that the electronic density of the corresponding 2-fluorobenzaldehydes might have some influence on this cascade reaction. 2-Fluorobenzaldehydes having an electron-withdrawing group were preferred substrates to those with an electron-donating group (Table 2, entries 1–13). Thus, when the cascade reaction was carried out with 2-fluorobenzaldehyde possessing a methoxy or methyl group under optimized conditions using K_2CO_3 as a base, the yield was significantly decreased (Table 2, entries 8–13). For instance, only 15% of the desired product was isolated upon reacting **1i** with **2a** using K_2CO_3 as a base (Table 2, entry 8). However, the

Table 2 Scope of 2-fluorobenzaldehydes

		X + N $CHO+ N H_3C 2a$	^I 3 K ₂ D ₂ Et	CO ₃ /120° DMF		CO ₂ Et
	Alde	Aldehyde			ict	
Entry	1	R	Х	4	R	$\operatorname{Yield}^{b}(\%)$
1	1b	3-F	F	4ba	9-F	61
2	1c	5-F	F	4ca	7-F	64
3	1d	6-F	F	4da	6-F	12^c
4	1e	5-Br	F	4ea	7-Br	63
5	1 f	6-Cl	Cl	4fa	6-Cl	$(24)^{d}$
6	1g	5-CN	F	4ga	7-CN	47
7	1ĥ	$5-CF_3$	F	4ĥa	7-CF ₃	71
8	1i	5-CH ₃	F	4ia	7-CH ₃	$15(50)^{d}$
9	1j	3-CH ₃ O	F	4ja	9-CH ₃ O	$(52)^{d}$
10	1k	4-CH ₃ O	F	4ka	8-CH ₃ O	$(61)^d$
11	1l	5-CH ₃ O	F	4la	7-CH ₃ O	$(63)^{d}$
12	1m	6-CH ₃ O	F	4ma	6-CH ₃ O	$(38)^{d}$
13	1n	4,5-dimethoxy	F	4na	7,8-dimethoxy	$(36)^{d}$

^{*a*} All reactions were carried out in the presence of pyrazole (2a) (1.2 mmol), 2-fluorobenzaldehydes (1.0 mmol), and K₂CO₃ (3.0 mmol) in DMF (5 mL) for 8 h. ^{*b*} Isolated yields. ^{*c*} An adduct of **4da** with **2a** was obtained in a 36% yield (see Experimental section). ^{*d*} Cs₂CO₃ was used instead of K₂CO₃.



Entry	Pyrazole 2		Product 4	$\operatorname{Yield}^{b}(\%)$
1	2b	$\mathbf{X} = \mathbf{H}, \mathbf{R}_1 = \mathbf{C}\mathbf{H}_3, \mathbf{R}_2 = \mathbf{C}\mathbf{H}_3$	4ab	Not detected
2	2c	$\mathbf{X} = \mathbf{C}\mathbf{H}_3, \mathbf{R}_1 = \mathbf{C}\mathbf{H}_3, \mathbf{R}_2 = \mathbf{C}\mathbf{H}_3$	$R_3 = H$ 4ac	Not detected
3	2d	$X = CN, R_1 = CH_3, R_2 = CH_3$	$R_3 = H$ 4ad	34
4	2e	$X = F, R_1 = CH_3, R_2 = CH_3$	$R_3 = H$ 4ae	Not detected
5	2 f	$X = Cl, R_1 = CH_3, R_2 = CH_3$	$R_3 = H$ 4af	6 ^{<i>c</i>}
6	2g	$X = Br, R_1 = CH_3, R_2 = CH_3$	$R_3 = H$ 4ag	58 ^c
7	2h	$X = I, R_1 = CH_3, R_2 = CH_3$	$R_3 = H$ 4ah	12^c
8	2i	$X = CO_2Et$, $R_1 = CH_3$, $R_2 = H$	R ₃ = H 4ai	10
9	2i	$X = CO_2Et$, $R_1 = CH_2$, $R_2 = SCH_2$	$R_3 = H$ 4ai	79
10	_j 2k	$\mathbf{X} = \mathbf{CO}_{2}\mathbf{E}\mathbf{t} \mathbf{R}_{1} = \mathbf{CH}_{2}\mathbf{CH}_{2} \mathbf{R}_{2} = \mathbf{SCH}_{2}$	$R_3 = H$ 4ak	47 ^c
11	21	$X = H_{R_1} = CH_{R_2} = CF_{R_3}$	$R_3 = CH_3$	71 ^{<i>c</i>,<i>d</i>}
11	21	$M_{11}, M_{1} = 0.13, M_{2} = 0.13$	$R_3 = H$,1

^{*a*} All reactions were carried out in the presence of pyrazoles (1.2 mmol), 2-fluorobenzaldehyde (1a) (1.0 mmol), and K₂CO₃ (3.0 mmol) in DMF (5 mL) for 8 h. ^{*b*} Isolated yields. ^{*c*} Cs₂CO₃ was used instead of K₂CO₃. ^{*d*} Reaction time was 4 days.

yield was significantly improved to 50% when Cs_2CO_3 was used instead of K_2CO_2 .¹² Using Cs_2CO_3 as a base, 2-fluorobenzaldehyde possessing a methoxy functional group at either of the positions of the aromatic ring reacted with the pyrazole to give the desired compounds **4ja–4na** in modest yields (Table 2, entries 9–13). Although the less reactive 2-chlorobenzaldehyde could not react with **2a** (data not shown), the more electrondeficient 2,6-dichlorobenzaldehyde **1f** reacted with **2a** under the modified conditions using Cs_2CO_3 instead of K_2CO_3 to give the cascade product **4fa** in a low yield (Table 2, entry 5).

Scope of pyrazoles

To extend the scope of the pyrazole substrates for the $S_NAr/$ Knoevenagel cyclization cascade reaction, we next examined the reactions of 2-fluorobenzaldehyde **1a** with a variety of pyrazole derivatives **2b–l**. The results are shown in Table 3.

Although pyrazoles 2b and 2c bearing electron-rich or electron-neutral groups at the 4-position such as $-CH_3$ or -H could not react with 1a (Table 3, entries 1 and 2), pyrazole 2d bearing an electron-deficient cyano group (-CN) at the 4-position was able to react with 1a to afford the desired products 4ad with a moderate yield (Table 3, entry 3). We found that halogen atoms, except a fluorine atom, also function as available as an electron-deficient functional group at the 4-position (Table 3, entries 4–7). It is noteworthy that the cascade reaction with pyrazole 2g substituted by a bromo group at the 4-position remarkably reacted with 1a to give the desired

product **4ag** with a good yield, though pyrazoles **2f** and **2h**, possessing other halogen atoms, did not react well (Table 3, entries 4–7).

The substituent at the 3-position of the pyrazoles also strongly affected the present cascade reaction. When pyrazole 2i, not having a methyl group at the 3-position, was used instead of 2a, the corresponding cascade product 4ai was obtained in a very low yield (Table 3, entry 8). However, pyrazoles 2j and 2k bearing $-SCH_3$ at the 3-position was able to react with 1a to afford the desired product 4aj⁵ and 4ak with a good yield (Table 3, entries 9 and 10). It should be pointed out that pyrazole 2l bearing a CF₃ functional group at the 3-position reacts with 1a to afford the desired product 4al with a good yield (Table 3, entry 11). This experiment suggests to us that an electron-withdrawing group at the 4 position of the pyrazole is not necessary to induce the present cascade reaction.

Application to synthesis of new heterocycles related to pyrazolo[1,5-*a*]quinolines

In an effort to apply the present cascade reaction to the synthesis of new heterocycles related to pyrazolo[1,5-a]quinolines, we finally examined the cascade reaction of **1a** with heteroaromatic aldehydes **6** and **7** (Tables 4 and 5).

As shown in Table 4, both 2-fluoro- and 2-chloropyridin-3aldehydes **6a** and **6b** reacted with the pyrazole **2a** to give the expected adduct **8aa** in comparative yields (Table 4, entries 1 and 2). 3-Fluoropyridin-4-aldehyde **6c** reacted with the pyrazole

Table 4 The cascade reaction of 2a with pyridyl aldehydes 6 for synthesis of new heterocycles^a



^{*a*} All reactions were carried out in the presence of **2a** (1.2 mmol), **6** (1.0 mmol), and K_2CO_3 (3.0 mmol) in DMF (5 mL) for 8 h. ^{*b*} Isolated yields. ^{*c*} Cs₂CO₃ was used instead of K_2CO_3 . ^{*d*} DMSO was used instead of DMF.

 Table 5
 The cascade reaction of 2a with pyrazolyl aldehydes 7 for synthesis of new heterocycles^a



^{*a*} All reactions were carried out in the presence of **2a** (1.2 mmol), 7 (1.0 mmol), and K_2CO_3 (3.0 mmol) in DMF (5 mL) for 8 h. ^{*b*} Isolated yields. ^{*c*} Cs₂CO₃ was used instead of K_2CO_3 .



Fig. 1 ORTEP drawing of 9ca.

2a to give the expected adduct **8ca** in very low yields (Table 4, entry 3). However, the yield was significantly improved to 30% when DMSO was used instead of DMF.

5-Chloropyrazoles 7a-c having a substituent at the 1-position also reacted with 2a under these conditions to give new heterocycles 9aa-9ca in varied yields. We wish to point out that pyrazole 8c having an electron-withdrawing CF₃ group gave 9ca in a good yield (Table 5).

All new heterocycles **9aa–9ca** were identified by conventional spectroscopic means. The structure of **9ca** was further confirmed by X-ray crystallographic analysis (Fig. 1).

Conclusions

A convenient and general method for the synthesis of pyrazolo [1,5-a]quinolines and the related heterocycles has been developed. The method is based upon a cascade reaction through an aromatic nucleophilic substitution of 1*H*-pyrazoles with 2-fluorobenzaldehyde derivatives, followed by Knoevenagel cyclization of the resulting adducts. Our method potentially provides a variety of pyrazolo[1,5-a]quinolines and the related heterocycles without using any transition metal catalysts upon fine-tuning a combination of two readily available substrates.

Experimental section

General information

All reagents and solvents were pure analytical-grade materials purchased from commercial sources and were used without further purification except for 1H-pyrazoles 2d, 2j and 2k. Compounds 2d, 2j and 2k were synthesized by a known method.^{13,14} All melting points were taken on a Yanagimoto micromelting point apparatus and were uncorrected. IR spectra were recorded on a JASCO FTIR-620. Mass spectra were measured on a JEOL GCmate by electron ionization and a Micromass Autospec by electrospray ionization. Elemental analysis was performed on an Elemental Vavio EL. NMR spectra were obtained on a JEOL JNM-ECP400 NMR spectrometer (¹H NMR: 400 MHz), a Bruker DPX400 NMR spectrometer (¹H NMR: 400 MHz) or a Bruker AVANCE III NMR spectrometer (¹H NMR: 400 MHz and ¹³C NMR: 100 MHz). The chemical shift data for each signal on ¹H NMR were given in units of δ relative to CHCl₃ (δ = 7.26) for CDCl₃ solution. For ¹³C NMR spectra, the chemical shifts in CDCl₃ were relative to $CDCl_3$ (δ = 77.0) resonances. Column chromatography was carried out using 63-210 µm silica gel 60N (Kanto Chemical Co., Inc.). Analytical TLC was carried out with Merck plates precoated with silica gel 60F254 plates (0.25 mm). Crystallographic data (excluding structure factors) for the X-ray crystal structure analysis reported in this paper have been deposited with the Cambridge Crystallographic Data Center (CCDC) as supplementary publication No. CCDC 900469.

Typical procedure for the preparation of pyrazolo[1,5-*a*] quinolone 4aa

A mixture of 2-fluorobenzaldehyde **1a** (202 mg, 1.0 mmol), 3,5dimethyl-1*H*-4-pyrazolecarboxylate **2a** (125 mg, 1.2 mmol), and K_2CO_3 (420 mg, 3 mmol) in DMF (5 mL) was stirred at 120 °C for 8 h. After monitoring the end of the reaction on TLC, the mixture was cooled to room temperature and diluted with water. The resulting mixture was extracted with ethyl acetate twice. The combined organic layers were washed with water twice, dried over MgSO₄ and the solvent was removed *in vacuo* to afford a residue. The residue was purified by flash column chromatography (hexane : EtOAc = 5 : 1) on silica gel to afford pyrazolo[1,5-*a*]quinolone **4aa** (203 mg, 80% yield).





Reaction of 2,6-difluorobenzaldehyde (1d) with 2a (Table 2, entry 3)

Compound 1d (143 mg, 1 mmol) was treated with 2a (202 mg, 1 mmol) in the presence of K_2CO_3 (420 mg, 3 mmol) in DMF (5 mL) for 8 h at 120 °C in a similar manner for the preparation of 4aa. The crude product was purified by silica gel column chromatography. Elution with a mixture of hexane : EtOAc = 5 gave 4da (33 mg, 12.1%). Successive elution with EtOAc afforded the adduct 4daa (149 mg, 35.5%). The structure of 4daa is shown in Fig. 2.

Ethyl 2-methylpyrazolo[1,5-*a*]quinoline-3-carboxylate (4aa). Yield: 80%. Pale yellow solid. Mp. 84–85 °C. IR (neat): ν_{max} / cm⁻¹ 1698, 1617, 1561, 1549, 1272, 1124. ¹H-NMR (CDCl₃, 400 MHz) δ 8.56 (d, *J* = 8.5 Hz, 1H), 8.03 (d, *J* = 9.3 Hz, 1H), 7.79 (d, *J* = 7.7 Hz, 1H), 7.72–7.67 (m, 1H), 7.63 (d, *J* = 9.3 Hz, 1H), 7.49–7.45 (m, 1H), 4.40 (q, *J* = 7.3 Hz, 2H), 2.74 (s, 3H), 1.44 (t, *J* = 7.3 Hz, 3H). ¹³C-NMR (CDCl₃, 100 MHz) δ 164.31, 154.25, 140.25, 133.98, 129.99, 128.37, 127.84, 125.15, 123.42, 116.94, 115.85, 104.06, 59.85, 14.56, 14.51. MS (EI⁺) *m*/*z* 254 [M]⁺, 209 [base]⁺. HR-MS (ESI) calcd for C₁₅H₁₅N₂O₂ [M + H]⁺ requires 255.1134, found 255.1134. Anal. Calcd for C₁₅H₁₄N₂O₂: C, 70.85; H, 5.55; N, 11.02. Found: C, 70.72; H, 5.62; N, 10.91.

Ethyl 1-(2-formylphenyl)-3,5-dimethyl-1*H*-pyrazole-4-carboxylate (3aa). Yield: 7%. Pale yellow solid. Mp. 100–102 °C. IR (neat): ν_{max} /cm⁻¹ 1701. ¹H-NMR (CDCl₃, 400 MHz) δ 9.64 (s, 1H), 8.07 (dd, J = 7.7 Hz, 7.7 Hz, 1H), 7.74 (td, J = 7.7 Hz, 1.5 Hz, 1H), 7.63 (t, J = 7.7 Hz, 1H), 7.39 (d, J = 7.7 Hz, 1H), 4.35 (q, J = 7.1 Hz, 2H), 2.51 (s, 3H), 2.43 (s, 3H), 1.39 (t, J = 7.1 Hz, 3H). ¹³C-NMR (CDCl₃, 100 MHz) δ 188.89, 164.22, 152.11, 146.40, 140.38, 134.47, 132.51, 129.80, 128.87, 128.03, 111.13, 59.96, 14.39, 14.25, 12.26. HR-MS (ESI) calcd for C₁₅H₁₇N₂O₃ [M + H]⁺ requires 273.1239, found 273.1234. Anal. Calcd for C₁₅H₁₆N₂O₃: C, 66.16; H, 5.92; N, 10.29. Found: C, 66.04; H, 5.98; N, 10.01.

Ethyl 9-fluoro-2-methylpyrazolo[1,5-*a*]quinoline-3-carboxylate (4ba). Yield: 61%. White solid. Mp. 121–126 °C. IR (neat): ν_{max}/cm^{-1} 1696, 1571, 1551, 1324, 1272, 1228, 1105. ¹H-NMR (CDCl₃, 400 MHz) δ 8.13 (d, *J* = 9.3 Hz, 1H), 7.63 (dd, *J* = 1.9 Hz, 9.3 Hz, 1H), 7.59 (d, *J* = 6.9 Hz, 1H), 7.49–7.46 (m, 1H), 7.44–7.38 (m, 1H), 4.41 (q, *J* = 7.3 Hz, 2H), 2.76 (s, 3H), 1.45 (t, *J* = 7.3 Hz, 3H). ¹³C-NMR (CDCl₃, 100 MHz) δ 164.09, 154.68 (d, ³*J*_{CF} = 5.0 Hz), 152.20 (d, ¹*J*_{CF} = 256.6 Hz), 141.45, 127.46 (d, ⁴*J*_{CF} = 2.0 Hz), 126.43, 125.01 (d, ³*J*_{CF} = 7.6 Hz), 124.08 (d, ⁴*J*_{CF} = 4.2 Hz), 123.39 (d, ²*J*_{CF} = 7.9 Hz), 117.88, 116.97 (d, ²*J*_{CF} = 20.5 Hz), 103.64, 59.99, 14.70, 14.45. MS (EI⁺) *m/z* 272 [M]⁺, 227 [base]⁺. HR-MS (ESI) calcd for $C_{15}H_{14}N_2O_2F [M + H]^+$ requires 273.1039, found 273.1034. Anal. Calcd for $C_{15}H_{13}N_2O_2F$: C, 66.17; H, 4.81; N, 10.29. Found: C, 66.06; H, 4.92; N, 10.26.

Ethyl 7-fluoro-2-methylpyrazolo[1,5-*a*]quinoline-3-carboxylate (4ca). Yield: 64%. White solid. Mp. 145–146 °C. IR (neat): ν_{max}/cm^{-1} 1700, 1566, 1436, 1241, 1123, 808. ¹H-NMR (CDCl₃, 400 MHz) δ 8.59 (dd, *J* = 9.1 Hz, 4.8 Hz, 1H), 8.10 (d, *J* = 9.5 Hz, 1H), 7.59 (d, *J* = 9.5 Hz, 1H), 7.49–7.42 (m, 2H), 4.41 (q, *J* = 7.1 Hz, 2H), 2.74 (s, 3H), 1.45 (t, *J* = 7.1 Hz, 3H). ¹³C-NMR (CDCl₃, 100 MHz) δ 164.17, 159.77 (d, ¹*J*_{CF} = 245.6 Hz), 154.26, 139.74, 130.66, 126.94 (d, ⁴*J*_{CF} = 3.1 Hz), 124.56 (d, ³*J*_{CF} = 8.9 Hz), 112.88 (d, ²*J*_{CF} = 22.6 Hz), 104.32, 59.93, 14.50, 14.47. HR-MS (ESI) calcd for C₁₅H₁₄N₂O₂F [M + H]⁺ requires 273.1039, found 273.1035. Anal. Calcd for C₁₅H₁₃N₂O₂F: C, 66.17; H, 4.81; N, 10.29. Found: C, 66.04; H, 5.06; N, 10.51.

Ethyl 6-fluoro-2-methylpyrazolo[1,5-*a*]quinoline-3-carboxylate (4da). Yield: 12%. Pale yellow solid. Mp. 102–104 °C. IR (neat): ν_{max}/cm^{-1} 1699, 1615, 1454, 1268, 1108, 791. ¹H-NMR (CDCl₃, 400 MHz) δ 8.35 (d, *J* = 8.7 Hz, 1H), 8.09 (d, *J* = 9.4 Hz, 1H), 7.89 (d, *J* = 9.4 Hz, 1H), 7.66–7.61 (m, 1H), 7.18 (t, *J* = 8.7 Hz, 1H), 4.41 (q, *J* = 7.3 Hz, 2H), 2.73 (s, 3H), 1.45 (t, *J* = 7.3 Hz, 3H). ¹³C-NMR (CDCl₃, 100 MHz) δ 164.12, 158.85 (d, ¹*J*_{CF} = 253 Hz), 154.66, 140.32, 134.85 (d, ³*J*_{CF} = 6.2 Hz), 130.22 (d, ³*J*_{CF} = 9.2 Hz), 120.14 (d, ³*J*_{CF} = 5.4 Hz), 117.32 (d, ⁴*J*_{CF} = 1.3 Hz), 113.66 (d, ²*J*_{CF} = 19.3 Hz), 111.74 (d, ³*J*_{CF} = 4.0 Hz), 110.14 (d, ²*J*_{CF} = 19.9 Hz), 104.68, 60.00, 14.53, 14.50. MS (EI⁺) *m*/*z* 272 [M]⁺, 227 [base]⁺. HR-MS (ESI) calcd for C₁₅H₁₄N₂O₂F (M + H)⁺ requires 273.1039, found 273.1034. Anal. Calcd for C₁₅H₁₃N₂O₂F: C, 66.17; H, 4.81; N, 10.29. Found: C, 66.01; H, 5.00; N, 10.13.

Ethyl 6-{4-(ethoxycarbonyl)-3,5-dimethyl-1*H*-pyrazol-1-yl}-2methylpyrazolo[1,5-*a*]quinoline-3-carboxylate (4daa, an adduct of 4da with 2a). Yield: 36%. Pale yellow solid. Mp. 161–164 °C. IR (neat): ν_{max} /cm⁻¹ 1703, 1263, 1108. ¹H-NMR (CDCl₃, 400 MHz) δ 8.74 (d, *J* = 8.5 Hz, 1H), 8.05 (d, *J* = 9.6 Hz, 1H), 7.80 (t, *J* = 8.5 Hz, 1H), 7.46–7.43 (m, 1H), 7.12 (d, *J* = 9.6 Hz, 1H), 4.41–4.33 (m, 4H), 2.75 (s, 3H), 2.54 (s, 3H), 2.34 (s, 3H), 1.43–1.38 (m, 6H). ¹³C-NMR (CDCl₃, 100 MHz) δ 164.39, 164.00, 154.88, 152.06, 146.52, 140.02, 135.78, 134.67, 129.52, 124.46, 122.34, 121.18, 118.76, 117.49, 110.70, 104.79, 60.02, 59.94, 14.53, 14.45, 14.39, 12.09. MS (EI⁺) *m*/*z* 420 [M]⁺. HR-MS (ESI) calcd for C₂₃H₂₅N₄O₄ [M + H]⁺ requires 421.1876, found 421.1876. Anal. Calcd for C₂₃H₂₄N₄O₄: C, 65.70; H, 5.75; N, 13.33. Found: C, 65.75; H, 5.72; N, 13.05.

Ethyl 7-bromo-2-methylpyrazolo[1,5-*a*]quinoline-3-carboxylate (4ea). Yield: 63%. Pale yellow solid. Mp. 164–167 °C. IR (neat): ν_{max}/cm^{-1} 1699, 1122, 813. ¹H-NMR (CDCl₃, 400 MHz) δ 8.46 (d, *J* = 8.8 Hz, 1H), 8.08 (d, *J* = 9.5 Hz, 1H), 7.95 (d, *J* = 2.0 Hz, 1H), 7.79 (dd, *J* = 8.8 Hz, 2.0 Hz, 1H), 7.55 (d, *J* = 9.5 Hz, 1H), 4.41 (q, *J* = 7.1 Hz, 2H), 2.73 (s, 3H), 1.45 (t, *J* = 7.1 Hz, 3H). ¹³C-NMR (CDCl₃, 100 MHz) δ 164.07, 154.54, 140.04, 132.94, 132.74, 130.51, 126.52, 124.81, 118.47, 118.23, 117.66, 104.54, 59.99, 14.51, 14.49. HR-MS (ESI) calcd for C₁₅H₁₄N₂O₂Br [M + H]⁺ requires 333.0239, found 333.0239. Anal. Calcd for C₁₅H₁₃N₂O₂Br: C, 54.07; H, 3.93; N, 8.41. Found: C, 54.19; H, 3.97; N, 8.61. **Ethyl 6-chloro-2-methylpyrazolo**[1,5-*a*]quinoline-3-carboxylate (4fa). Yield: 24%. White solid. Mp. 116–118 °C. IR (neat): ν_{max}/cm^{-1} 1705, 1613, 1127, 1092, 791. ¹H-NMR (CDCl₃, 400 MHz) δ 8.54 (d, *J* = 8.0 Hz, 1H), 8.14 (d, *J* = 9.7 Hz, 1H), 8.07 (d, *J* = 9.7 Hz, 1H), 7.62 (t, *J* = 8.0 Hz, 1H), 7.56 (dd, *J* = 8.0 Hz, 1.2 Hz, 1H), 4.42 (q, *J* = 7.3 Hz, 2H), 2.74 (s, 3H), 1.46 (t, *J* = 7.3 Hz, 3H). ¹³C-NMR (CDCl₃, 100 MHz) δ 164.05, 154.76, 140.03, 134.91, 132.65, 129.82, 125.60, 123.93, 121.45, 117.87, 114.84, 104.47, 59.98, 14.51, 14.48. HR-MS (ESI) calcd for C₁₅H₁₄N₂O₂Cl [M + H]⁺ requires 289.0744, found 289.0740.

Ethyl 7-cyano-2-methylpyrazolo[1,5-*a*]quinoline-3-carboxylate (4ga). Yield: 47%. Pale brown solid. Mp. 220–224 °C. IR (neat): $\nu_{\rm max}/{\rm cm}^{-1}$ 2227, 1697, 1613, 1542, 1431, 1324, 1270, 1159, 1124, 814. ¹H-NMR (CDCl₃, 400 MHz) δ 8.68 (d, *J* = 8.8 Hz, 1H), 8.16 (d, *J* = 9.4 Hz, 1H), 8.16 (d, *J* = 1.8 Hz, 1H), 7.91 (dd, *J* = 8.8 Hz, 1.8 Hz, 1H), 7.64 (d, *J* = 9.4 Hz, 1H), 4.43 (q, *J* = 7.2 Hz, 2H), 2.75 (s, 3H), 1.46 (t, *J* = 7.2 Hz, 3H). ¹³C-NMR (CDCl₃, 100 MHz) δ 163.81, 155.49, 140.83, 135.73, 133.36, 132.02, 126.55, 123.21, 119.13, 118.21, 117.22, 108.92, 105.47, 60.22, 14.57, 14.47. HR-MS (ESI) calcd for C₁₆H₁₄N₃O₂ [M + H]⁺ requires 280.1086, found 280.1081. Anal. Calcd for C₁₆H₁₃N₃O₂: C, 68.81; H, 4.69; N, 15.05. Found: C, 68.79; H, 4.76; N, 15.09.

Ethyl 2-methyl-7-(trifluoromethyl) pyrazolo[1,5-*a*]quinoline-3-carboxylate (4ha). Yield: 71%. Yellow solid. Mp. 135–139 °C. IR (neat): ν_{max}/cm^{-1} 1702, 1316, 1113. ¹H-NMR (CDCl₃, 400 MHz) δ 8.68 (d, *J* = 8.5 Hz, 1H), 8.13 (d, *J* = 9.4 Hz, 1H), 8.09 (s, 1H), 7.91 (dd, *J* = 8.8 Hz, 1.5 Hz, 1H), 7.67 (d, *J* = 9.4 Hz, 1H), 4.41 (q, *J* = 7.3 Hz 2H), 2.75 (s, 3H), 1.45 (t, *J* = 7.3 Hz, 3H). ¹³C-NMR (CDCl₃, 100 MHz) δ 163.95, 155.02, 140.67, 135.44, 127.32 (q, ²*J*_{CF} = 33.0 Hz), 127.27, 126.17 (q, ³*J*_{CF} = 3.2 Hz), 125.92 (q, ³*J*_{CF} = 4.0 Hz), 125.23 (q, ¹*J*_{CF} = 272.0 Hz), 122.83, 118.52, 116.79, 104.97, 60.08, 14.54, 14.47. MS (EI⁺) *m/z* 322 [M]⁺, 277 [base]⁺. HR-MS (ESI) calcd for C₁₆H₁₄N₂O₂F₃ [M + H]⁺ requires 323.1007, found 323.1007. Anal. Calcd for C₁₆H₁₃N₂O₂F₃: C, 59.63; H, 4.07; N, 8.09. Found: C, 59.66; H, 4.35; N, 8.28.

Ethyl 2,7-dimethyl-2-methylpyrazolo[1,5-*a*]quinoline-3-carboxylate (4ia). Yield: 15% (using K₂CO₃), 50% (using Cs₂CO₃). White solid. Mp. 103–104 °C. IR (neat): ν_{max}/cm^{-1} 1697, 823. ¹H-NMR (CDCl₃, 400 MHz) δ 8.45 (d, *J* = 8.5 Hz, 1H), 8.01 (d, *J* = 9.2 Hz, 1H), 7.58 (d, *J* = 9.2 Hz, 1H), 7.58 (s, 1H), 7.53 (dd, *J* = 8.5 Hz, 1.5 Hz, 1H), 4.40 (q, *J* = 7.3 Hz, 2H), 2.73 (s, 3H), 2.51 (s, 3H), 1.44 (t, *J* = 7.3 Hz, 3H). ¹³C-NMR (CDCl₃, 100 MHz) δ 164.33, 154.01, 139.90, 134.90, 132.14, 131.46, 127.83, 127.62, 123.43, 116.80, 115.60, 103.75, 59.76, 21.12, 14.50, 14.49. MS (EI⁺) *m*/*z* 268 [M]⁺, 223 [base]⁺. HR-MS (ESI) calcd for C₁₆H₁₇N₂O₂ (M + H)⁺ requires 285.1290, found 269.1292. Anal. Calcd for C₁₆H₁₆N₂O₂: C, 71.62; H, 6.01; N, 10.44. Found: C, 71.41; H, 5.88; N, 10.42.

Ethyl 9-methoxy-2-methylpyrazolo[1,5-*a*]quinoline-3-carboxylate (4ja). Yield: 52%. White solid. Mp. 101–105 °C. IR (neat): ν_{max}/cm^{-1} 1697, 1566, 1271, 1098. ¹H-NMR (CDCl₃, 400 MHz) δ 8.15 (d, *J* = 9.2 Hz, 1H), 7.64 (d, *J* = 9.2 Hz, 1H), 7.44–7.43 (m, 2H), 7.28–7.25 (m, 1H), 4.41 (q, *J* = 7.2 Hz, 2H), 4.14 (s, 3H), 2.79 (s, 3H), 1.45 (t, *J* = 7.2 Hz, 3H). ¹³C-NMR (CDCl₃, 100 MHz) δ 164.35, 154.04, 150.34, 141.96, 128.39, 126.28, 125.30, 125.21, 121.07, 117.34, 112.82, 102.93, 59.87, 57.24, 15.02, 14.46. HR-MS (ESI) calcd for $C_{16}H_{17}N_2O_3~[M~+~H]^+$ requires 285.1239, found 285.1239. Anal. Calcd for $C_{16}H_{16}N_2O_3$: C, 67.59; H, 5.67; N, 9.85. Found: C, 67.51; H, 5.58; N, 10.04.

Ethyl 8-methoxy-2-methylpyrazolo[1,5-*a*]quinoline-3-carboxylate (4ka). Yield: 61%. Pale yellow solid. Mp. 122–124 °C. IR (neat): ν_{max}/cm^{-1} 1697, 1616, 1549, 1217, 1108. ¹H-NMR (CDCl₃, 400 MHz) δ 8.00 (d, *J* = 2.5 Hz, 1H), 7.92 (d, *J* = 9.2 Hz, 1H), 7.70 (d, *J* = 8.7 Hz, 1H), 7.61 (d, *J* = 9.2 Hz, 1H), 7.10 (dd, *J* = 8.7 Hz, 2.5 Hz, 1H), 4.41 (q, *J* = 7.1 Hz, 2H), 4.03 (s, 3H), 2.76 (s, 3H), 1.45 (t, *J* = 7.1 Hz, 3H). ¹³C-NMR (CDCl₃, 100 MHz) δ 164.33, 161.37, 154.33, 140.67, 135.25, 129.64, 127.61, 117.48, 115.93, 114.02, 103.55, 97.13, 59.75, 55.86, 14.57, 14.50. HR-MS (ESI) calcd for C₁₆H₁₇N₂O₃ [M + H]⁺ requires 285.1239, found 285.1242. Anal. Calcd for C₁₆H₁₆N₂O₃: C, 67.59; H, 5.67; N, 9.85. Found: C, 67.76; H, 5.46; N, 9.88.

Ethyl 7-methoxy-2-methylpyrazolo[1,5-*a*]quinoline-3-carboxylate (4la). Yield: 63%. Pale yellow solid. Mp. 119–122 °C. IR (neat): ν_{max}/cm^{-1} 1690, 1272, 1127, 806. ¹H-NMR (CDCl₃, 400 MHz) δ 8.49 (d, *J* = 9.2 Hz, 1H), 8.03 (d, *J* = 9.2 Hz, 1H), 7.58 (d, *J* = 9.2 Hz, 1H), 7.32 (dd, *J* = 8.9 Hz, 2.7 Hz, 1H), 7.18 (d, *J* = 2.7 Hz, 1H), 4.40 (q, *J* = 7.3 Hz, 2H), 3.92 (s, 3H), 2.72 (s, 3H), 1.44 (t, *J* = 7.3 Hz, 3H). ¹³C-NMR (CDCl₃, 100 MHz) δ 164.33, 156.94, 153.86, 139.26, 128.88, 127.32, 124.43, 119.68, 117.35, 117.24, 108.78, 103.61, 59.74, 55.61, 14.50, 14.47. MS (EI⁺) *m*/*z* 284 [M]⁺. HR-MS (ESI) calcd for C₁₆H₁₇N₂O₃ [M + H]⁺ requires 285.1239, found 285.1238. Anal. Calcd for C₁₆H₁₆N₂O₃: C, 67.59; H, 5.67; N, 9.85. Found: C, 67.69; H, 5.70; N, 9.83.

Ethyl 6-methoxy-2-methylpyrazolo[1,5-*a*]quinoline-3-carboxylate (4ma). Yield: 38%. White solid. Mp. 132–133 °C. IR (neat): ν_{max} /cm⁻¹ 1701, 1617, 1105, 789. ¹H-NMR (CDCl₃, 400 MHz) δ 8.16 (d, *J* = 8.2 Hz, 1H), 8.09 (d, *J* = 9.6 Hz, 1H), 8.00 (d, *J* = 9.6 Hz, 1H), 7.62 (t, *J* = 8.2 Hz, 1H), 6.90 (d, *J* = 8.2 Hz, 1H), 4.41 (q, *J* = 7.4 Hz, 2H), 4.02 (s, 3H), 2.74 (s, 3H), 1.45 (t, *J* = 7.4 Hz, 3H). ¹³C-NMR (CDCl₃, 100 MHz) δ 164.49, 156.19, 154.45, 140.62, 134.87, 130.51, 122.43, 115.62, 114.82, 108.22, 104.87, 103.81, 59.90, 56.00, 14.67, 14.62. HR-MS (ESI) calcd for C₁₆H₁₇N₂O₃ [M + H]⁺ requires 285.1239, found 285.1230.

Ethyl 7,8-dimethoxy-2-methylpyrazolo[1,5-*a*]quinoline-3-carboxylate (4na). Yield: 36%. White solid. Mp. 150–152 °C. IR (neat): ν_{max} /cm⁻¹ 1692, 1247, 1112. ¹H-NMR (CDCl₃, 400 MHz) δ 8.00 (s, 1H), 7.94 (d, *J* = 9.2 Hz, 1H), 7.57 (d, *J* = 9.2 Hz, 1H), 7.26 (s, 1H), 7.16 (s, 1H), 4.40 (q, *J* = 7.2 Hz, 2H), 4.11 (s, 3H), 4.01 (s, 3H), 2.75 (s, 3H), 1.44 (t, *J* = 7.2 Hz, 3H). ¹³C-NMR (CDCl₃, 100 MHz) δ 164.41, 154.11, 152.09, 147.86, 139.77, 129.46, 127.01, 117.29, 114.67, 107.84, 103.10, 97.43, 59.69, 56.50, 56.12, 14.53. HR-MS (ESI) calcd for C₁₇H₁₉N₂O₄ [M + H]⁺ requires 315.1345, found 315.1345. Anal. Calcd for C₁₇H₂₀N₂O₄: C, 64.96; H, 5.77; N, 8.91. Found: C, 64.71; H, 5.79; N, 8.74.

3-Cyano-2-methylpyrazolo[1,5-*a*]quinoline (4ad). Yield: 34%. White solid. Mp. 160–161 °C. IR (neat): $\nu_{\text{max}}/\text{cm}^{-1}$ 1614, 1471,

1304, 804, 756, 744. ¹H-NMR (CDCl₃, 400 MHz) δ 8.55 (d, J = 8.5 Hz, 1H), 7.84 (d, J = 7.7 Hz, 1H), 7.78–7.73 (m, 1H), 7.71 (d, J = 9.2 Hz, 1H), 7.56 (d, J = 9.2 Hz, 1H), 7.56–7.51 (m, 1H), 2.64 (s, 3H). ¹³C-NMR (CDCl₃, 100 MHz) δ 152.73, 139.75, 134.77, 129.61, 128.53, 125.84, 124.65, 123.23, 115.98, 114.81, 77.21, 54.96, 14.35. MS (EI⁺) m/z 207 [M] ⁺. HR-MS (ESI) calcd for C₁₃H₁₀N₃ [M + H]⁺ requires 208.0875, found 208.0880.

3-Chloro-2-methylpyrazolo[1,5-*a*]quinoline (4af). Yield: 6%. White solid. Mp. 91–95 °C. IR (neat): $\nu_{\text{max}}/\text{cm}^{-1}$ 1487, 1310, 801, 747. ¹H-NMR (CDCl₃, 400 MHz) δ 8.48 (d, *J* = 8.5 Hz, 1H), 7.74 (d, *J* = 7.7 Hz, 1H), 7.67–7.63 (m, 1H), 7.45–7.34 (m, 2H), 7.35 (d, *J* = 9.2 Hz, 1H), 2.51 (s, 3H). ¹³C-NMR (CDCl₃, 100 MHz) δ 147.82, 135.00, 134.55, 129.65, 128.55, 125.03, 124.66, 123.06, 114.75, 114.02, 102.13, 11.67. MS (EI⁺) *m*/*z* 216 [M]⁺, 140 [base]⁺. HR-MS (ESI) calcd for C₁₂H₁₀N₂Cl [M + H]⁺ requires 217.0533, found 217.0532.

3-Bromo-2-methylpyrazolo[1,5-*a*]quinoline (4ag). Yield: 58%. White solid. Mp. 116–118 °C. IR (neat): ν_{max}/cm^{-1} 1478, 1305, 802, 743. ¹H-NMR (CDCl₃, 400 MHz) δ 8.49 (d, *J* = 8.5 Hz, 1H), 7.74 (d, *J* = 7.7 Hz, 1H), 7.67–7.63 (m, 1H), 7.45–7.40 (m, 2H), 7.33 (d, *J* = 9.6 Hz, 1H), 2.51 (s, 3H). ¹³C-NMR (CDCl₃, 100 MHz) δ 149.35, 136.59, 134.54, 129.61, 128.51, 125.35, 124.63, 123.07, 114.74, 114.62, 87.81, 12.60. MS (EI⁺) *m/z* 260 [M - 1]⁺, 140 [base]⁺. HR-MS (ESI) calcd for C₁₂H₁₀N₂Br [M + H]⁺ requires 261.0027, found 261.0032. Anal. Calcd for C₁₂H₉N₂Br: C, 55.20; H, 3.47; N, 10.73. Found: C, 55.28; H, 3.58; N, 10.74.

3-Iodo-2-methylpyrazolo[1,5-*a*]quinoline (4ah). Yield: 12%. White solid. Mp. 135–138 °C. IR (neat): ν_{max}/cm^{-1} 1614, 1472, 1303, 803, 755, 743. ¹H-NMR (CDCl₃, 400 MHz) δ 8.50 (d, *J* = 8.5 Hz, 1H), 7.75 (d, *J* = 8.1 Hz, 1H), 7.67–7.62 (m, 1H), 7.46–7.39 (m, 2H), 7.29 (d, *J* = 9.2 Hz, 1H), 2.53 (s, 3H). ¹³C-NMR (CDCl₃, 100 MHz) δ 154.72, 141.61, 134.17, 130.69, 128.74, 128.71, 125.80, 123.37, 115.94, 114.16, 85.03, 13.14. MS (EI⁺) *m*/*z* 308 [M]⁺. HR-MS (ESI) calcd for C₁₂H₁₀N₂I [M + H]⁺ requires 308.9889, found 308.9893. Anal. Calcd for C₁₂H₉N₂I: C, 46.78; H, 2.94; N, 9.09. Found: C, 46.63; H, 3.13; N, 9.11.

Ethyl pyrazolo[1,5-*a*]quinoline-3-carboxylate (4ai). Yield: 10%. Pale yellow solid. Mp. 101–102 °C. IR (neat): ν_{max}/cm^{-1} 1703, 1244, 1218, 1097. ¹H-NMR (CDCl₃, 400 MHz) δ 8.62 (d, J = 8.5 Hz, 1H), 8.44 (s, 1H), 8.10 (d, J = 9.2 Hz, 1H), 7.84 (d, J = 8.0 Hz, 1H), 7.76–7.72 (m, 1H), 7.70 (d, J = 9.2 Hz, 1H), 7.84 (d, J = 7.3 Hz, 1H), 4.41 (q, J = 7.3 Hz, 2H), 1.43 (t, J = 7.3 Hz, 3H). ¹³C-NMR (CDCl₃, 100 MHz) δ 163.57, 143.52, 139.08, 134.40, 130.15, 128.47, 128.13, 125.61, 123.60, 116.72, 116.01, 106.55, 60.12, 14.50. MS (EI⁺) m/z 240 [M]⁺, 195 [base]⁺; HR-MS (ESI) calcd for C₁₄H₁₃N₂O₂ [M + H]⁺ requires 241.0977, found 241.0972. Anal. Calcd for C₁₄H₁₂N₂O₂: C, 69.99; H, 5.03; N, 11.66. Found: C, 69.96; H, 4.93; N, 11.73.

Ethyl 2-(methylthio)pyrazolo[1,5-*a*]quinoline-3-carboxylate (4aj). Yield: 79%. Pale yellow solid. Mp. 115–117 °C. IR (neat): $\nu_{\text{max}}/\text{cm}^{-1}$ 1695, 1614, 1105. ¹H-NMR (CDCl₃, 400 MHz) δ 8.57 (d, *J* = 8.5 Hz, 1H), 8.00 (d, *J* = 9.4 Hz, 1H), 7.81 (d, *J* = 7.7 Hz, 1H), 7.73–7.69 (m, 1H), 7.66 (d, *J* = 9.4 Hz, 1H), 7.50–7.47 (m, 1H), 4.42 (q, *J* = 7.3 Hz, 2H), 2.73 (s, 3H), 1.45 (t, *J* = 7.3 Hz, 3H). ¹³C-NMR (CDCl₃, 100 MHz) δ 163.59, 154.87, 140.75,

133.81, 130.10, 128.38, 128.17, 125.12, 123.05, 116.34, 115.83, 103.25, 60.15, 14.52, 13.75. MS (EI⁺) m/z 286 [M]⁺. HR-MS (ESI) calcd for $C_{15}H_{15}N_2O_2S$ [M + H]⁺ requires 286.0864, found 287.0854. Anal. Calcd for $C_{15}H_{14}N_2O_2S$: C, 62.92; H, 4.93; N, 9.78. Found: C, 62.73; H, 4.91; N, 9.87.

Ethyl 2-(methylthio)-4-methyl-pyrazolo[1,5-*a*]quinoline-3-carboxylate (4ak). Yield: 47%. Pale yellow solid. Mp. 112–114 °C. IR (neat): ν_{max}/cm^{-1} 1713, 11525, 1078. ¹H-NMR (CDCl₃, 400 MHz) δ 8.56 (d, *J* = 8.4 Hz, 1H), 7.70 (d, *J* = 8.0 Hz, 1H), 7.64 (t, *J* = 7.7 Hz, 1H), 7.47 (t, *J* = 8.0 Hz, 1H), 7.40 (s, 1H), 4.41 (q, *J* = 7.2 Hz, 2H), 2.77 (s, 3H), 2.72 (s, 3H), 1.45 (t, *J* = 7.2 Hz, 3H). ¹³C-NMR (CDCl₃, 100 MHz) δ 163.48, 154.91, 140.51, 132.73, 129.02, 127.85, 127.16, 126.73, 125.08, 122.98, 115.88, 105.07, 60.54, 21.85, 14.39, 14.26. HR-MS (ESI) calcd for C₁₆H₁₇N₂O₂S [M + H]⁺ requires 301.1011, found 301.1012. Anal. Calcd for C₁₆H₁₆N₂O₂S: C, 63.98; H, 5.37; N, 9.33. Found: C, 63.91; H, 5.32; N, 9.35.

Ethyl 2-trifluoromethyl-pyrazolo[1,5-*a*]quinoline-3-carboxylate (4al). Yield: 71%. Pale yellow solid. Mp. 78–79 °C. IR (neat): ν_{max} /cm⁻¹ 1124, 811. ¹H-NMR (CDCl₃, 400 MHz) δ 8.63 (d, *J* = 8.4 Hz, 1H), 7.80 (dd, *J* = 7.9 Hz, 1.1 Hz, 1H), 7.73–7.69 (m, 1H), 7.547.25 (m, 3H), 6.86 (s, 1H). ¹³C-NMR (CDCl₃, 100 MHz) δ 143.89 (q, ²*J*_{CF}, 38.2 Hz), 138.63, 134.45, 129.80, 128.45, 125.98, 125.86, 123.66, 121.60 (q, ¹*J*_{CF}, 272.0 Hz), 116.38, 116.00, 98.01 (q, ³*J*_{CF}, 2.0 Hz). HR-MS (ESI) calcd for C₁₂H₈N₂F₃ [M + H]⁺ requires 237.0640, found 237.0643.

Ethyl 2-methylpyrazolo[1,5-*a*][1,8]naphthyridine-3-carboxylate (8aa). Yield: 51% (for 6a), 41% (for 6b). White solid. Mp. 125–129 °C. IR (neat): ν_{max}/cm^{-1} 1700, 1619, 1550, 1414, 1109. ¹H-NMR (CDCl₃, 400 MHz) δ 8.88 (dd, *J* = 4.6 Hz, 1.9 Hz, 1H), 8.18 (dd, *J* = 7.7 Hz, 1.9 Hz, 1H), 8.15 (d, *J* = 9.5 Hz, 1H), 7.61 (d, *J* = 9.5 Hz, 1H), 7.51 (dd, *J* = 9.4 Hz, 4.6 Hz, 1H), 4.42 (q, *J* = 7.3 Hz, 2H), 2.79 (s, 3H), 1.44 (t, *J* = 7.3 Hz, 3H). ¹³C-NMR (CDCl₃, 100 MHz) δ 163.98, 155.37, 150.58, 143.87, 142.03, 137.11, 126.55, 121.37, 118.38, 118.26, 105.37, 60.05, 14.63, 14.41. MS (EI⁺) *m*/*z* 255 [M]⁺, 210 [base]⁺. HR-MS (ESI) calcd for C₁₄H₁₃N₃O₂Na [M + H]⁺ requires 278.0905, found 278.0903.

Ethyl 2-methylpyrazolo[1,5-*a*][1,7]naphthyridine-3-carboxylate (8ca). Pale brown solid. Mp. 118–120 °C. IR (neat): ν_{max} / cm⁻¹ 1695, 1549, 1431, 1276, 1128. ¹H-NMR (CDCl₃, 400 MHz) δ 9.94 (s, 1H), 8.68 (d, *J* = 5.4 Hz, 1H), 8.24 (d, *J* = 9.3 Hz, 1H), 7.64 (d, *J* = 5.4 Hz, 1H), 7.59 (d, *J* = 9.3 Hz, 1H), 4.41 (q, *J* = 7.3 2H), 2.75 (s, 3H), 1.45 (t, *J* = 7.3 Hz, 3H). ¹³C-NMR (CDCl₃, 100 MHz) δ 163.82, 154.86, 144.47, 140.28, 139.68, 129.33, 127.81, 125.53, 121.89, 120.54, 105.34, 60.13, 14.46, 14.45; EI⁺ *m*/*z* 255 [M]⁺, 210 [base]⁺; HR-MS (ESI) calcd for C₁₄H₁₄N₃O₂ (M + H)⁺ requires 256.1086, found 256.1085.

Ethyl 1,3,7-trimethyl-1*H*-dipyrazolo[1,5-*a*:4',3'-*e*]pyridine-6carboxylate (9aa). Yield: 49%. White solid. Mp. 140–142 °C. IR (neat): ν_{max}/cm^{-1} 1698, 1632, 1505, 1267, 1106. ¹H-NMR (CDCl₃, 400 MHz) δ 7.72 (d, *J* = 9.3 Hz, 1H), 7.50 (d, *J* = 9.3 Hz, 1H), 4.50 (s, 3H), 4.40 (q, *J* = 7.3 Hz, 2H), 2.70 (s, 3H), 2.52 (s, 3H), 1.44 (t, *J* = 7.3 Hz, 3H). ¹³C-NMR (CDCl₃, 100 MHz) δ 164.29, 155.08, 142.95, 142.50, 135.62, 121.51, 110.53, 110.08, 102.00, 64.00, 59.83, 38.05, 14.58, 14.49, 12.09. MS (EI+) *m/z* 272 [M]⁺. HR-MS (ESI) calcd for C₁₄H₁₇N₄O₂ [M + H]⁺ requires 273.1352, found 273.1349. Anal. Calcd for $C_{14}H_{16}N_4O_2$: C, 61.75; H, 5.92; N, 20.58. Found: C, 61.73; H, 5.76; N, 20.54.

Ethyl 1-benzyl-3,7-dimethyl-1*H*-dipyrazolo[1,5-*a*:4',3'-*e*]pyridine-6-carboxylate (9ba). Yield: 27%. White solid. Mp. 128–130 °C. IR (neat): $\nu_{\text{max}}/\text{cm}^{-1}$ 1699, 1627, 1505, 1252, 1119, 1088. ¹H-NMR (CDCl₃, 400 MHz) δ 7.75 (d, J = 9.2 Hz, 1H), 7.52(d, J = 9.2 Hz, 1H), 7.40 (d, J = 7.7 Hz, 2H), 7.30-7.21 (m, 3H), 6.13 (s, 2H), 4.40 (q, J = 7.3 Hz, 2H), 2.71 (s, 3H), 2.52 (s, 3H), 1.43 (t, J = 7.3 Hz, 3H). ¹³C-NMR (CDCl₃, 100 MHz) δ 164.35, 155.12, 143.80, 142.62, 137.31, 135.29, 128.55, 128.18, 127.73, 121.52, 110.74, 110.35, 102.74, 59.85, 53.85, 14.68, 14.52, 12.18. MS (EI⁺) m/z 348 [M]⁺, 91 [base]⁺; HR-MS (ESI) calcd for $C_{20}H_{21}N_4O_2 [M + H]^+$ requires 349.1665, found 349.1663. Anal. Calcd for C₂₀H₂₀N₄O₂: C, 68.95; H, 5.79; N, 16.08. Found: C, 69.03; H, 5.78; N, 16.08.

Ethyl 1,7-dimethyl-3-(trifluoromethyl)-1*H*-dipyrazolo[1,5*a*:4',3'-*e*]pyridine-6-carboxylate (9ca). Yield: 64%. White solid. Mp. 148–150 °C. IR (neat): ν_{max}/cm^{-1} 1702, 1509, 1266, 1180, 1120, 1091. ¹H-NMR (CDCl₃, 400 MHz) δ 7.90 (d, *J* = 9.6 Hz, 1H), 7.64 (d, *J* = 9.6 Hz, 1H), 4.63 (s, 3H), 4.41 (q, *J* = 7.3 Hz, 2H), 2.72 (s, 3H), 1.44 (t, *J* = 7.3 Hz, 3H). ¹³C-NMR (CDCl₃, 100 MHz) δ 163.84, 155.60, 142.35, 135.64, 135.33 (q, ²*J*_{CF} = 39.3 Hz), 121.05 (q, ¹*J*_{CF} = 269.3 Hz), 120.12, 113.92, 107.93, 103.86, 60.16, 39.47, 14.49, 14.42. MS (EI⁺) *m*/*z* 326 [M]⁺, 281 [base]⁺. HR-MS (ESI) calcd for C₁₄H₁₄N₄O₂F₃ [M + H]⁺ requires 327.1069, found 327.1064. Anal. Calcd for C₁₄H₁₃N₄O₂F₃: C, 51.54; H, 4.02; N, 17.17. Found: C, 51.36; H, 4.28; N, 17.16.

Acknowledgements

The authors thank Mr Haruhiko Fukaya (the Analytical Center, Tokyo University of Pharmacy and Life Sciences) for the X-ray crystallographic analysis.

Notes and references

- 1 S. Lober, H. Hubuner and P. Gmeiner, *Bioorg. Med. Chem. Lett.*, 1999, **9**, 97.
- 2 H. C. Shen, D. Fa-Xiang, Q. Deng, L. C. Wilsie, M. L. Krsmanovic, A. K. Taggart, E. Carballo-Jane, N. Ren, C. Tian-Quan, W. Tsuei-Ju, K. K. Wu, K. Cheng, Q. Chen, M. S. Wolff, X. Tong, T. G. Holt, M. G. Waters,

M. L. Hammond, J. R. Tata and S. L. Colletti, *J. Med. Chem.*, 2009, **52**, 2587.

- S. Philipp, H. Holger, J. Dominik. D. Christof, G. Anja and
 B. Esther, (Merck Patent GmbH., Germany). *PCT Int. Appl.*,
 WO 2010086089 A1 20100805, 2010.
- 4 M. W. Welsch, S. A. Snyder and B. R. Stockwell, *Curr. Opin. Chem. Biol.*, 2010, **14**, 1.
- 5 (a) Y. Tamura, Y. Miki and M. Ikeda, J. Heterocycl. Chem., 1975, 12, 119; (b) R. J. Sundberg and J. E. Ellis, J. Heterocycl. Chem., 1982, 19, 573; (c) Y. Tominaga, Y. Ichihara, T. Mori, C. Kamio and A. Hosomi, J. Heterocycl. Chem., 1990, 27, 263.
- 6 Y. Tominaga and A. Hosomi, *J. Heterocycl. Chem.*, 1987, 25, 119.
- 7 (a) J. J. Mousseau, A. Fortier and A. B. Charette, *Org. Lett.*, 2010, 12, 516; (b) J. J. Mousseau, J. A. Bull, C. L. Ladd, A. Fortier, D. S. Roman and A. B. Charette, *J. Org. Chem.*, 2011, 76, 8243.
- 8 N. Umeda, K. Hirano, T. Satoh, N. Shibata, H. Sato and M. Miura, J. Org. Chem., 2011, 76, 13.
- 9 (a) D. Csanyi, G. Timari and G. Hajos, Synth. Commun., 1999, 29, 3959; (b) J. Zhao, C. Wu, P. Li, W. Ai, H. Chen, C. Wang, R. C. Larock and F. Shi, J. Org. Chem., 2011, 76, 6837; (c) H. Gnichtel and B. Moeller, Liebigs Ann. Chem., 1981, 10, 1751.
- A. R. Katritzky, C. A. Ramsden, J. A. Joule and J. A. V. V. Zhdankin, *Reactions of Alkylazoles Involving Traces of Reactive Anions: Handbook of Heterocyclic Chemistry*, Elsevier, The Netherlands, 3rd edn, 2010, pp. 564–565.
- 11 Although several new syntheses of aza- or oxa-fused heterocycles based on Knoevenagel condensation have been reported, most of the methods are required to introduce a direct-activating group such as $-CO_2Et$ and -CN into the α -position to the reacting methylene for inducing the Knoevenagel condensation.¹⁵.
- 12 Recently, Cs_2CO_3 was reported to be a better base than K_2CO_3 in an S_NAr reaction of inactivated 2-fluorobenzenes with 1*H*-pyrazoles: F. Diness and P. D. Fairlie, *Angew. Chem., Int. Ed.*, 2012, **51**, 8012.
- 13 E. C. Taylor and W. R. Purdum, Heterocycles, 1977, 6, 1865.
- 14 A. Alberola, L. F. Antolin, A. M. Gonzalez, M. A. Laguna and F. J. Pulido, *J. Heterocycl. Chem.*, 1986, 24, 1035.
- 15 (a) Q. Cai, Z. Li, L. Fu, D. Pei and K. Ding, Org. Lett., 2010,
 12, 1500; (b) Y. L. Choi, H. S. Lim and J.-N. Heo, Org. Lett.,
 2012, 14, 5102.